SaveGaea is a synthetic biology startup producing GMP-grade psychedelic APIs using engineered bacterial fermentation. Based in the U.S., the company aims to solve supply chain and scalability challenges for researchers, biotech firms, and future clinical sponsors developing psychedelic therapies. Unlike traditional extraction or chemical synthesis, SaveGaea’s platform enables consistent, cost-effective production suited for regulated environments. Currently in its early stages, the company is focused on proof of concept, DEA licensure, and facility planning. Long-term, SaveGaea intends to operate as a CDMO partner, supporting clinical innovation with high-quality psychedelic compounds for research and therapeutic development.